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Background: In this study, we investigated the role and expression of interleukin (IL)217A and IL-22
in chronic lymphocytic leukemia.
Methods: We evaluated the expression of markers above on CLL by ELISA, qRT-PCR, flow cytometric
analysis and nonparametric Kruskal–Wallis test.
Results: Quantitative RT-PCR revealed that the mRNA levels of IL-17A and IL-22 in PBMCs of CLL
patients were upregulated compared with those from healthy subjects (mean6 SD: 1.9660.232
vs.0.726 0.15, P< 0.001 and mean6SD: 2.4560.534 vs.0.816 0.26, P< 0.001, respectivily). In
addition, findings showed that the IL-17A and IL-22 plasma level was significantly elevated than that
from healthy control group (P < 0.001). The median IL-17A and IL-22 in CLL patients and healthy con-
trol group were 48.286 17.2 pg mL21; 20.016 11.16 pg mL21 and 58.68623.4 pg mL21;16.476
10.31 P< 0.001, respectively. The levels of IL-17A and IL-22 was not significantly associated with the
different stages of disease (Rai stages; Kruskal–Wallis test P> 0.05).No significant relationship was
found between expression of CD38 and higher median serum levels of IL-17A in patients, but patients
with negative expression of ZAP-70 showed a significant association with higher median serum levels of
IL-17A compared with healthy subjects. (57.84 pg mL21 vs. 31.67 pg mL21; P5 0.016).
Conclusion: IL-22 is elevated and associated with CD38 and Zap-70 expression in patients with CLL. No
significant correlation was found between expression of CD38 and increased levels of IL-17A, negative
expression of ZAP-70 showed a significant association with increased levels of IL-17A. VC 2016 International
Clinical Cytometry Society
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Chronic lymphocytic leukemia (CLL), is one of the
most common leukemia in adults and in the elderly
worldwide (1), with an incidence of 22–30 per 100,000
in Western countries (2). It is characterized to be a het-
erogeneous disease with variable clinical pattern and
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evolution (3). Survival times from initial diagnosis have
been indicated to be between 2 and 20 years (4). Differ-
ent prognostic markers have been previously evaluated
and these studies focused on evaluation of new prognos-
tic markers that may be valuable in subgroups with
favorable and poor clinical outcome in early CLL (4–7).
These markers may be beneficial in early stage, progres-
sive form, where patients can be treated before progres-
sion occurs (8). Many of these markers are mostly used
clinical practice such as heavy-chain variable region
(IgVH), CD38 levels, ZAP-70 expression, interphase fluo-
rescence in situ hybridization (iFISH) abnormalities
(4–9). It has been indicated that multifunctional cyto-
kines are involved in the progression of malignancies via
bidirectional regulation of inflammatory responses. Cyto-
kines has been indicated to be an associated factor with
survival in B-CLL cells and may be correlated with dis-
ease progression by upregulating antiapoptotic proteins
and by furnishing prosurvival signals (10). Recent inves-
tigations have indicated that Th17 and Th22 cells and
their effector cytokines can be involved in the pathogen-
esis of various autoimmune diseases and human tumors,
such as Crohn’s disease, lung and gastric cancer (11).
Benham et al. found that increased IL-17 and IL-22 pro-
ducing CD41 T cells can be considered as a feature of
psoriatic arthritis (12). The role of Th22 and IL-22 in the
pathogenesis of many kinds of solid tumors and also
hematological malignancies has been shown including
ALL, MDS and AML (13–15). The impact of Th17 in
autoimmune diseases and against extracellular bacteria,
various, fungi, and viruses is shown, but in cancer is
controversial (16,17). However, its role has been
described in a limited number of hematological malig-
nancies such as AML, non-Hodgkin lymphoma and CLL
(13,18,19).
This study was aimed to investigate the potential role
of Th17 and IL-22 in chronic lymphocytic leukemia in
association with clinical factors.
MATERIAL AND METHODS
Patients and Samples
Blood samples from 78 patients with CLL were
obtained in the Clinics of Hematology–Oncology between
2013 and 2015, Tehran, Iran. All samples were collected
before the start of any anticancer therapy including che-
motherapy or anti-inflammatory drugs. Twenty-eight
healthy volunteers were also included as controls (13 sex-
matched and age-matched men and also 15 women; age
range, 34–75 years, and median age: 62). It is worth
noting that none of the CLL patients or control individual
had kidney failure, active infections, and inflammatory
diseases.
Disease staging was classified based on the Rai classifi-
cation system (20). Our research was performed accord-
ing the Helsinki declaration and patients have signed an
informed consent. Samples were centrifuged at 4000 rpm
at 48C for 20 min and plasma samples stored at 2808C
until use.
Enzyme-linked Immunosorbent Assay (ELISA)
Plasma concentrations were measured using a com-
mercial enzyme-linked immunosorbent assay (ELISA) kit
(Human IL-17A, IL-22 Immunoassay; R&D Systems). Elisa
method was performed according to the manufacturer’s
recommendations.
Extraction of RNA and qRT-PCR
Quantitative RT-PCR was performed to measure the
mRNA levels of IL-17A and IL-22 in peripheral blood
mononuclear cell (PBMC). For this purpose, total RNA
was extracted using miRNeasy Serum/Plasma Kit (Qia-
gen), according to the manufacturer’s instructions. Tran-
scriptor High Fidelity cDNA Synthesis Kit (Roche) was
used to synthesize cDNA according to the manufac-
turer’s protocol.
QRT-PCR was performed on Applied Biosystems 7500
real-time PCR system with TaqMan TaqMan reagents spe-
cific for human IL-17A and IL-22. GAPDH was served as
a control and relative expression levels of mRNAs was
counted with the threshold cycle (CT) method-fold
change (2-DDCT).
Flow Cytometric Analysis of ZAP-70 and CD38
All procedures were performed as described previous-
ly (21), and a cutoff point of 20% (positive cells) was
determined for ZAP-7 and CD38.
IGVH Gene Mutational Status
IgVH genes sequencing was performed (11), and
obtained sequence were then aligned using GenBank
databases.
Statistical Analysis
Nonparametric Kruskal–Wallis test followed by a Dunn
multiple comparisons test were performed to analyze dif-
ferences in cytokine levels between groups. All the statis-
tical analyses were performed with Prism Version 5.00
(GraphPad Software) and SAS 9.2 (SAS Institute). Statisti-
cal analysis was considered to be statistically significant
P< 0.05.
RESULTS
IL-17A and IL-22 Plasma Levels and Their Association
with Clinical Factors
Our finding showed that the IL-17A plasma level was
significantly elevated than that from healthy control group
(P < 0.001). The median IL-17A level in CLL patients was
48.286 17.2 pg mL21, and it was 20.016 11.16 pg mL21
in healthy control group. Furthermore, the plasma level of
IL-22 was strongly higher as compared to healthy control
Group (58.686 23.4 pg mL21;16.476 10.31, P < 0.001).
The levels of IL-17A and IL-22 was not significantly associ-
ated with the different stages of disease (Rai stages;
Kruskal–Wallis test P> 0.05) (Fig. 1).
No significant relationship was found between expres-
sion of CD38 and higher median serum levels of IL-17A
in patients, but patients with negative expression of
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ZAP-70 showed a significant association with higher
median serum levels of IL-17A compared with healthy
subjects. (57.84 pg mL21 vs.31.67 pg mL21; P5 0.016).
On the other hand, the high plasma level of IL-22 in CLL
patients was linked to the patients with positive CD38
and ZAP-70 compared with healthy subjects (All
P< 0.001).
The IgVH genes mutation was detected in 51 cases and
unmutated genes were found in 27 cases. CD38 expres-
sion was >20% in 33 cases, and ZAP-70 expression was
>20% in 28 cases (Table 1). A significant associating was
found between the plasma levels of IL-22 and IgVH muta-
tional status, but it was not significant in high level of IL-
17A.
Moreover, other clinical parameters were not correlated
with plasma levels of IL-17A and IL-22 including sex, age,
Hb levels, platelet or lymphocyte count, and B2m levels.
MRNA Levels of IL-17 and L-22
Quantitative RT-PCR was applied to evaluate the
mRNA levels of IL-17A and IL-22 in PBMCs.
Our result showed that the mRNA levels of IL-17A in
PBMCs of CLL patients was upregulated compared with
those from healthy subjects (mean6 SD: 1.966 0.232
vs.0.726 0.15, P< 0.001). In addition, overexpression of
IL-22 mRNA levels were presented in CLL patients as
competed to healthy subjects (mean6 SD: 2.456 0.534
vs. 0.816 0.26, P< 0.001) (Fig. 2).
DISCUSSION
The role of Th17 in autoimmune diseases and against
extracellular bacteria, various, fungi, and viruses has
been previously described, but in cancer remain unclear
(16,17).
Our results indicated that the IL-17A plasma level was
significantly elevated than that from healthy control sub-
jects. Also, mRNA levels of IL-17A in PBMCs of CLL patients
was upregulated compared with those from healthy sub-
jects No significant association was found between expres-
sion of CD38 and higher median serum levels of IL-17A in
patients. However, patients with negative expression of
ZAP-70 showed a significant correlation with increased
median serum levels of IL-17A than in healthy individuals.
Th17 cells distribution has been detected to show different
pattern in solid tumors or hematological diseases. Elevated
Serum Level of IL-17 found as a prognostic biomarker in
multiple myeloma (22). Increased levels of circulating
Th17 subset were detected in tumor tissues in uterine cer-
vical cancer (23). Previous studies indicated that Th17 cells
decreased in chronic myeloid leukemia (24,25). On the
other hand, the elevated level of Th17 cells has been
detected in multiple myeloma and acute myeloid leukemia.
It has been suggested that the increased numbers of Th17
cells is association with favorable prognosis in patients
FIG. 1. IL-17A and IL-22 plasma levels in patents with CLL compared with normal control group. [Color figure can be viewed at wileyonlinelibrary.com]
Table 1
Clinical and Laboratory Features at CLL Diagnosis (Number
of Patients578)
Characteristics
No. of
patients (%)
Age (years) 78 Median: 59;
Range 33–81
Gender
Male 43 55.12
Female 35 44.87
RAI stage
0 31 39.74
1 16 20.51
2 9 11.53
3 10 12.82
4 12 15.38
IGHV mutation status
Mutated (2%) 51 65.38
Unmutated (<2%) 27 34.61
CD 38
Positive 33 37.17
Negative 45 62.82
Zap 70
Positive 28 30.76
Negative 38 53.84
Unknown 12 15.38
b2-microglobulin, mg L21
<2 65 83.33
>2 13 16.66
Hemoglobin: g dL21
<10 15 19.23
>10 63 80.76
Platelet count: (3109/l) 78 Median 161, range
between 3–646
WBC count (3109/l) 78 Median 48.54, range
between 1.5–455
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with CLL (26). Some studies have also indicated IL-171 T
cells are associated with tumor pathogenesis in a little
number of malignancies such as ovarian and renal cell car-
cinoma (27). In consist with our study, Hus et al. (4) found
that the IL-17A concentration of peripheral blood was sig-
nificantly higher in CLL patients compared with healthy
subjects. Moreover, they reported that the high plasma lev-
el of IL-17A inversely related to the stage of disease, but we
didn’t find significant association between the levels of IL-
17A and the different stages of disease. Furthermore, the
high level of Th17 was detected in peripheral blood mono-
nuclear cells and bone marrow mononuclear cells in
patients with acute myeloid leukemia. Also, it was indicat-
ed that high Th17 cell frequency is associated with poor
prognosis (28). Th17 cells in involved in the pathogenesis
of AML and may be a prognostic predictor (28). Th17/IL-
17 axes may be associated with development of non-
Hodgkin’s lymphoma, and acute myeloid leukemia (18,29).
On the other hand that the downregulation of IL-17-
producing T cells and expansion of Treg cells, has been
reported to be correlated with progression of CLL (19).
Further comprehensive and functional studies are required
for clarification of the role of IL-17 in CLL patients.
In the present study, the plasma level of IL-22 was
strongly higher as compared to healthy control group.
High IL-22 mRNA levels were presented in CLL patients
as competed to healthy subjects. In addition, the high
plasma level of IL-22 in CLL patients was linked to the
patients with positive CD38 and ZAP-70 compared with
healthy subjects. Regulatory role of IL-22 in some biolog-
ical process has been indicated such as cell cycle con-
trol, cell growth and proliferation. In addition, IL-22
might be involved in tumor genesis. The role of Th sub-
sets in the immune pathogenesis of CLL needed further
clarification. It has been recently found that Th22 cells
and IL-22 may participate in ALL, MDS and AML
(13–15). Recent study indicated that Th22 frequency
and level of IL-22 were increased in AML patients than
in healthy subjects (30). Increased expression of periph-
eral Th22 was detected to be correlated with the late-
stage MDS as compared to early-stage MDS (15). In this
study, the levels of IL-22 were not significantly associat-
ed with the different stages of disease (Rai stages).
Liu et al. suggested that circulating Th22 cells as well
as Th17 cells are significantly increased in the peripheral
blood of gastric cancer patients with tumor progression.
Yu et al. indicated that plasma levels of IL-22 and per-
centage of Th22 and Th17 subsets were markedly elevat-
ed in AML patients (13). Moreover, plasma levels of the
cytokines IL-1b, IL-6, IL-17, IL-22, IL-23, and TGF-b1
were strongly elevated in AML patients (28). The fre-
quencies of PB or BM Th22 cells were high in ND CML
patients (24). High level of plasma IL-22 was detected in
B-CLL patients compared with healthy individuals in
chronic lymphocytic leukemia. Patients presenting with
high CD38 expression had significantly higher plasma
IL-22 levels compared with those with low CD38 (31).
This finding is in accordance with our result that the
high plasma level of IL-22 in CLL patients was linked to
the patients with positive CD38 and ZAP-70 compared
with healthy subjects. CD38 was described as a novel
marker of poor prognosis. In the current study, No sta-
tistically significant difference was determined between
plasma levels of IL-22 in different d stages.
A significant associating was found between the plas-
ma levels of IL-22 and IgVH mutational status, but it was
not significant in high level of IL-17A.
There was no significant association between IL-22
levels and other clinical parameters including age, sex,
Hb levels, platelet or lymphocyte count, B2m levels.
Our findings are more or less in agreement with Heiba
et al. (31). CD38 is an unfavorable prognosis and is asso-
ciated with activation and proliferation of CLL cells
(32,33). The role CD38 has been described in signal
transduction, aschemotaxis and homing more efficient,
was found that this marker act as an integrator of prolif-
erative and migratory signals.
It has been suggested that high plasma IL-22 levels,
high expression of IL-22 and high expression of CD38
may be involved in synergy to activate genetic programs
relevant for proliferative responses and inhibition of apo-
ptosis. And can be associated with poor prognosis in B-
CLL patients (31) as well as different interleukins has
been reported as prognostic biomarker on cancers (34).
However, functional studies are needed for more clarifi-
cation. In conclusion, the present study suggested that
IL-22 is elevated and its expression is associated with
CD38 and Zap-70 expressions in patients with CLL. Neg-
ative expression of ZAP-70 showed a significant associa-
tion with increased levels of IL-17A, while no significant
correlation was found between expression of CD38 and
increased levels of IL-17A.
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